NCT05175430View on ClinicalTrials.gov

Effects of SERT Inhibition on the Subjective Response to LSD in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 24, 2022

Primary Completion Date

February 20, 2024

Study Completion Date

March 7, 2024

Conditions
Healthy
Interventions
DRUG

Paroxetine

Paroxetine (per os) will be used as pharmacological tool to downregulate 5-HT1/2 receptors.

DRUG

Lysergic Acid Diethylamide

LSD (per os) will be used to see if 5-HT 1/2 receptors were downregulated by paroxetine.

DRUG

Placebo

Placebo (per os) for the Paroxetine condition will be used to compare the data from the study day with LSD between both arms.

Trial Locations (1)

4031

Clinical Pharmacology & Toxicology, University Hospital Basel, Basel

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER